Multiple myeloma highlights from ASCO 2025
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, highlights the promising developments in multiple myeloma from the 2025 ASCO meeting. He discusses several ongoing clinical trials, the subcutaneous administration of isatuximab, novel cellular therapies, and approaches for difficult-to-treat patients. This interview took place during the 2023 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео Multiple myeloma highlights from ASCO 2025 канала VJHemOnc – Video Journal of Hematology & HemOnc
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео Multiple myeloma highlights from ASCO 2025 канала VJHemOnc – Video Journal of Hematology & HemOnc
Speaker: Claudio Cerchione Institution: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Event: ASCO 2025 Format: Interview Subject: Multiple Myeloma Field: Trial Updates Field: Treatment Medicines: Antibodies Field: Immuno-Oncology Medicines: Belantamab mafodotin Trial: IMROZ Trial: CEPHEUS Medicines: Isatuximab
Комментарии отсутствуют
Информация о видео
3 июня 2025 г. 19:00:02
00:04:03
Другие видео канала
